Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dapsone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    21 result(s) found for: Dapsone. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-000390-30 Sponsor Protocol Number: ML20128 Start Date*: 2006-05-18
    Sponsor Name:Helsinki University Central Hospital, Skin and Allergy Hospital
    Full Title: A phase II trial assessing dapsone topical gel in the prevention and treatment of erlotinib associated rash
    Medical condition: The study population are patients with non-small cell lung carcinoma eligible for treatment with erlotinib (TarcevaTM). A significant number of these patients develop acne-like rash as a side effec...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001245-41 Sponsor Protocol Number: 2005/Diaminodiphenylsulfon/1 Start Date*: 2005-09-23
    Sponsor Name:Department of Dermatology, Hospital of the Medical University Graz
    Full Title: A single-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Dapsone in adult patients with cutaneous leukocytoclastic vasculitis
    Medical condition: Cutaneous leukocytoclastic vasculitis is an inflammatory vascular disease and is manifested clinically by a spectrum of cutaneous lesions, although “papable purpura” is its clinical hallmark. The p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006613-10 Sponsor Protocol Number: TMC207LEP3001 Start Date*: 2024-08-13
    Sponsor Name:Janssen Pharmaceutica NV
    Full Title: A Phase 3, Multicenter, Open-label, Rater-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline for the Treatment of Multibacillary Leprosy When Combined With Rifampicin...
    Medical condition: Multibacillary Leprosy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10024232 Leprosy, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2016-004666-26 Sponsor Protocol Number: 2015/208/HP Start Date*: 2017-07-19
    Sponsor Name:CHU-Hôpitaux de Rouen
    Full Title: Randomised double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid
    Medical condition: severe forms of mucous membrane pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002835-27 Sponsor Protocol Number: DRP-05-12 Start Date*: 2012-09-07
    Sponsor Name:Dr. Ritsert Pharma
    Full Title: Double-blind, randomized clinical study to determine the efficacy of Anestherit® 10% on histamine-induced pruritus and UVB-light induced slight sunburn in healthy subjects.
    Medical condition: Histamine-induced pruritus UVB-light-induced slight sunburn
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020063-21 Sponsor Protocol Number: ILUVIT1 Start Date*: 2010-06-15
    Sponsor Name:Charité-Universitätsmedizin
    Full Title: “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”
    Medical condition: Urticarial vasculitis
    Disease: Version SOC Term Classification Code Term Level
    12.1 10048820 Urticarial vasculitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003828-23 Sponsor Protocol Number: ML39310 Start Date*: 2017-04-11
    Sponsor Name:Charité - Universitätsmedizin Berlin; Dpt. of Dermatology and Allergy
    Full Title: A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)
    Medical condition: Schnitzler’s syndrome (SchS)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10062908 Schnitzler's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002915-23 Sponsor Protocol Number: ARGX-113-1904 Start Date*: 2021-01-25
    Sponsor Name:argenx BV
    Full Title: A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)
    Medical condition: Pemphigus Vulgaris or Pemphigus Foliaceus
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10052802 Pemphigus vulgaris LLT
    20.0 100000004858 10057069 Pemphigus foliaceus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) HU (Completed) BG (Completed) ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-004774-97 Sponsor Protocol Number: C-935788-057 Start Date*: 2019-10-23
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Medical condition: Warm antibody autoimmune hemolytic anemia (wAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Completed) ES (Completed) CZ (Completed) HU (Completed) DK (Completed) DE (Completed) AT (Completed) BE (Completed) NL (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-000756-42 Sponsor Protocol Number: MEX0111 Start Date*: Information not available in EudraCT
    Sponsor Name:Dompé s.p.a.
    Full Title: A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid.
    Medical condition: active bullous pemphigoid
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003564-37 Sponsor Protocol Number: PRN1008-005 Start Date*: 2016-04-21
    Sponsor Name:Principia Biopharma Australia Pty Ltd
    Full Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagn...
    Medical condition: Pemphigus: Pemphigus Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002100-41 Sponsor Protocol Number: ARGX-113-1801 Start Date*: 2019-11-01
    Sponsor Name:argenx BVBA
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients With Primary Immun...
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) HU (Completed) CZ (Completed) ES (Completed) PL (Completed) BE (Completed) DE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004032-21 Sponsor Protocol Number: ARGX-113-2004 Start Date*: 2021-05-07
    Sponsor Name:argenx BV
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immu...
    Medical condition: Primary immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10083843 Primary immune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) PT (Completed) DE (Completed) BG (Completed) NO (Completed) DK (Completed) GR (Completed) IT (Completed) FR (Completed) RO (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004103-12 Sponsor Protocol Number: TAK-079-1004 Start Date*: 2021-02-22
    Sponsor Name:Takeda Development Center Americas, Inc. (Takeda)
    Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Efficacy of TAK-079 in Patients with Persistent/Chronic Primary Immune Thrombocytopenia
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004851 10050245 Autoimmune thrombocytopenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SI (Completed) BG (Completed) HR (Completed) IT (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-005525-11 Sponsor Protocol Number: WX21956 Start Date*: 2009-04-24
    Sponsor Name:F Hoffmann-La Roche Ltd
    Full Title: A randomized, placebo controlled, double-blind, parallel group study to compare the safety and reduction in disease activity with the combination of rituximab (MabThera) and tocilizumab (Actemra) v...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    13.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2009-011206-42 Sponsor Protocol Number: INCB 28050-201 Start Date*: 2009-08-18
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double Blind, Placebo Controlled, Dose Ranging, Parallel Group, Phase 2 Study of INCB028050 Compared to Background Therapy in Patients with Active Rheumatoid Arthritis with Inadequate...
    Medical condition: Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2017-003051-35 Sponsor Protocol Number: DER-201701 Start Date*: 2018-10-09
    Sponsor Name:Rheinische Friedrich-Wilhelms-Universität Bonn
    Full Title: Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BEL...
    Medical condition: Patients with lupus erythematosus (LE) with active, therapy-resistant skin manifestations receiving Standard of Care (SOC) therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10025135 Lupus erythematosus (incl subtypes) HLT
    21.1 100000004859 10025134 Lupus erythematosus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003509-72 Sponsor Protocol Number: 20200234 Start Date*: 2021-10-21
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GR (Completed) PL (Prematurely Ended) AT (Completed) BG (Prematurely Ended) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000328-16 Sponsor Protocol Number: 20170588 Start Date*: 2019-09-23
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy
    Medical condition: Active Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Prematurely Ended) PT (Prematurely Ended) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000831-21 Sponsor Protocol Number: HZNP-DAX-202 Start Date*: 2023-02-06
    Sponsor Name:Horizon Therapeutics Ireland DAC
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP TRIAL TO INVESTIGATE THE EFFICACY AND SAFETY OF DAXDILIMAB SUBCUTANEOUS INJECTION IN REDUCING DISEASE ACTIVITY I...
    Medical condition: Discoid Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    25.0 100000004858 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 19:23:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA